Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen.


Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 02 11 2018
revised: 23 11 2018
accepted: 26 11 2018
pubmed: 7 12 2018
medline: 16 11 2019
entrez: 4 12 2018
Statut: ppublish

Résumé

Characteristics and risk factors (RFs) of invasive fungal disease (IFD) have been little studied in the setting of umbilical cord blood transplantation (UCBT). We retrospectively included 205 single-unit myeloablative UCBT recipients with a median follow-up of 64 months. Fifty-six episodes of IFD were observed in 48 patients (23%) at a median time of 123 days after stem cell infusion. Invasive mold disease (IMD) occurred in 42 cases, 38 of them (90%) caused by invasive aspergillosis whereas invasive yeast disease (IYD) occurred in 14 cases, most of them due to candidemia (n = 12, 86%). The 5-year cumulative incidence of IFD, IMDs, and IYDs was 24% 19%, and 7%, respectively. In multivariate analysis, three RFs for IMDs were identified: age >30 years (HR 3.5, P = 0.017), acute grade II-IV graft-versus-host disease (HR 2.3, P = 0.011), and ≥1 previous transplant (HR 3.1, P = 0.012). The probability of IMDs was 2.5%, 14%, and 33% for recipients with none, 1, or 2-3 RFs, respectively (P < 0.001). Among IFD, IMDs had a negative effect on non-relapse mortality in multivariate analysis (HR 1.6, P = 0.039). IMDs showed a negative impact on overall survival (HR 1.59, P = 0.018). Invasive mold disease were very common and serious complication after UCBT.

Identifiants

pubmed: 30506598
doi: 10.1111/ejh.13202
doi:

Substances chimiques

Anti-Infective Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

331-340

Informations de copyright

© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Juan Montoro (J)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.

Jaime Sanz (J)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.
Department of Medicine, University of Valencia, Valencia, Spain.

José I Lorenzo (JI)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Pau Montesinos (P)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.

Rebeca Rodríguez-Veiga (R)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Miguel Salavert (M)

Department of Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Eva González (E)

Department of Microbiology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Manuel Guerreiro (M)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Carlos Carretero (C)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Aitana Balaguer (A)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Inés Gómez (I)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Pilar Solves (P)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Guillermo F Sanz (GF)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.

Miguel A Sanz (MA)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.
Department of Medicine, University of Valencia, Valencia, Spain.

José L Piñana (JL)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
CIBERONC, Instituto Carlos III, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH